Browse

Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors

Cited 13 time in Web of Science Cited 12 time in Scopus
Authors
Kim, Tae Won; Ryu, Min-Hee; Lee, Heungnam; Sym, Sun Jin; Chang, Heung Moon; Lee, Kyung Hee; Shin, Dong Bok; Lee, Jung Shin; Kang, Yoon-Koo; Bang, Yung-Jue; Kang, Won Ki; Park, Young Suk; Lee, Jae-Lyun
Issue Date
2009
Publisher
ALPHAMED PRESS
Citation
ONCOLOGIST; Vol.14 5; 540-547
Keywords
ImatinibGastrointestinal stromal tumorPDGFRA mutationKoreanKIT mutation
Abstract
Purpose. This study analyzed the relationship between treatment outcome and kinase mutational status in Korean patients with advanced gastrointestinal stromal tumors (GISTs). Experimental Design. Clinical data were collected from 113 consecutive patients with metastatic or unresectable GISTs treated with imatinib from June 2001 through June 2005 at five institutions in Korea. KIT exons 9, 11, 13, and 17 and PDGFRA exons 12 and 18 were examined. Results. The median patient age was 57 years (range, 31-82 years). The overall response rate was 67.2%. KIT mutations were found in exon 11 (n = 92, 81.4%) and exon 9 (n = 10, 8.8%). One patient had a PDGFRA exon 18 mutation. The overall mutation rate was 91.2%. Response rates were 68.4%, 50.0%, and 80.0% in patients with KIT exon 11 mutations, KIT exon 9 mutations, and no kinase mutations, respectively. With a median follow-up of 49.0 months, the median progression-free survival (PFS) time was 42.0 months and median overall survival (OS) time was not reached. PFS and OS times did not differ significantly according to KIT genotype. Conclusion. This study was unable to find an association between KIT mutational status and clinical outcome of imatinib in Korean patients with advanced GISTs. There was a trend toward better outcomes for patients with wild-type KIT or exon 11 mutations compared with exon 9 mutations, although this was not statistically significant. Compared with previous studies in western populations, these results suggest that ethnic differences may influence the relationship between KIT genotype and clinical outcome to imatinib. The Oncologist 2009;14:540-547
ISSN
1083-7159
Language
English
URI
http://hdl.handle.net/10371/76375
DOI
https://doi.org/10.1634/theoncologist.2008-0145
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse